EICHOR
● Terminated
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Condition: Infectious Pneumonia · Severe COVID-19 · Sponsor: Dompé Farmaceutici S.p.A
About this study
Primary objective: \- To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28. Key secondary objectives: * To compare the efficacy of reparixin vs placebo in all-cause mortality at day 180. * To compare the efficacy of reparixin vs placebo in proportion of patients alive and discharged at day 28 * To compare the efficacy of reparixin vs placebo in ventilatory-free days at day 28. * To compare the efficacy of reparixin vs placebo in proportion of patients with IMV (or ECMO) by day 28. * To compare the efficacy of reparixin vs placebo in length of primary hospital stay. Other efficacy objectives \- To compare the efficacy of reparixin vs placebo on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: \- To evaluate safety and tolerability of oral reparixin versus placebo in the specific clinical setting.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (74)
| MD Banner University Medical Center /Arizona University | Tucson, Arizona, United States | — |
| UCI Health | Orange, California, United States | — |
| Denver Health | Denver, Colorado, United States | — |
| MedStar Health Research Institute-Hyatteville, Maryland | Washington D.C., District of Columbia, United States | — |
| Research Alliance Inc. | Clearwater, Florida, United States | — |
| University of Florida-Jacksonville | Jacksonville, Florida, United States | — |
| Emory Johns Creek Hospital | Atlanta, Georgia, United States | — |
| Augusta University Health - Augusta University Medical Center | Augusta, Georgia, United States | — |
| Northwestern University, Feinberg School of Medicine | Chicago, Illinois, United States | — |
| Methodist Hospital | Gary, Indiana, United States | — |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | — |
| Newton-Wellesley Hospital | Newton, Massachusetts, United States | — |
+ 62 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05254990